Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Theravance Biopharma, Inc. before investing.

In this article, we go over a few key elements for understanding Theravance Biopharma, Inc.’s stock price such as:

• Theravance Biopharma, Inc.’s current stock price and volume
• Why Theravance Biopharma, Inc.’s stock price changed recently
• Upgrades and downgrades for TBPH from analysts
• TBPH’s stock price momentum as measured by its relative strength

About Theravance Biopharma, Inc. (TBPH)

Before we jump into Theravance Biopharma, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Want to learn more about Theravance Biopharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Theravance Biopharma, Inc..

Theravance Biopharma, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Theravance Biopharma, Inc.’s stock price was $16.860.

Theravance Biopharma, Inc. is up 0.06% from its previous closing price of $16.850.

During the last market session, Theravance Biopharma, Inc.’s stock traded between $16.850 and $16.880. Currently, there are approximately 51.28 million shares outstanding for Theravance Biopharma, Inc..

Theravance Biopharma, Inc.’s price-earnings (P/E) ratio is currently at 7.6, which is low compared to the Pharmaceuticals industry median of 20.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Theravance Biopharma, Inc. Stock Price History

Theravance Biopharma, Inc.’s (TBPH) price is currently down 0.82% so far this month.

During the month of July, Theravance Biopharma, Inc.’s stock price has reached a high of $17.280 and a low of $16.800.

Over the last year, Theravance Biopharma, Inc. has hit prices as high as $21.030 and as low as $10.822. Year to date, Theravance Biopharma, Inc.’s stock is down 9.89%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Theravance Biopharma, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Theravance Biopharma, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Theravance Biopharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Theravance Biopharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Theravance Biopharma, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Theravance Biopharma, Inc. (TBPH) by visiting AAII Stock Evaluator.

Relative Price Strength of Theravance Biopharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Theravance Biopharma, Inc. has a weighted four-quarter relative price strength of 5.69%, which translates to a Momentum Score of 72 and is considered to be Strong.

Want to learn more about how Theravance Biopharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Theravance Biopharma, Inc. Stock Price: Bottom Line

As of July 31, 2026, Theravance Biopharma, Inc.’s stock price is $16.860, which is up 0.06% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Theravance Biopharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.